@article{d0236555da6243baa7a1d3f537d9fa91,
title = "Stratified psychiatry: Tomorrow's precision psychiatry?",
abstract = "Here we review the paradigm-change from one-size-fits-all psychiatry to more personalized-psychiatry, where we distinguish between {\textquoteleft}precision psychiatry{\textquoteright} and {\textquoteleft}stratified psychiatry{\textquoteright}. Using examples in Depression and ADHD we argue that stratified psychiatry, using biomarkers to facilitate patients to best {\textquoteleft}on-label{\textquoteright} treatments, is a more realistic future for implementing biomarkers in clinical practice.",
keywords = "ADHD, Biomarker, Depression, EEG, Precision psychiatry, Stratified psychiatry",
author = "Martijn Arns and \{van Dijk\}, Hanneke and Luykx, \{Jurjen J.\} and \{van Wingen\}, Guido and Sebastian Olbrich",
note = "Funding Information: MA is unpaid chairman of the non-profit Brainclinics Foundation, a minority shareholder in neuroCare Group (Munich, Germany), and a co-inventor on several patents related to EEG, neuromodulation and psychophysiology, but receives no royalties related to these patents; Research Institute Brainclinics received research funding from neuroCare Group (Munich, Germany), Brain Resource (Sydney, Australia), Urgotech (France), Neuroscience Software (US) and equipment support from Deymed, neuroConn, Compumedics and Magventure. GvW received research funding from Philips. The other authors have nothing to declare. Publisher Copyright: {\textcopyright} 2021",
year = "2022",
month = feb,
doi = "10.1016/j.euroneuro.2021.10.863",
language = "English",
volume = "55",
pages = "14--19",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
}